Milestone Pharmaceuticals
MIST
34 hedge funds and large institutions have $117M invested in Milestone Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 5 closing their positions.
691% more call options, than puts
Call options by funds: $2.68M | Put options by funds: $339K
0% more funds holding
Funds holding: 34 → 34 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
0.96% less ownership
Funds ownership: 68.99% → 68.03% (-0.96%)
15% less capital invested
Capital invested by funds: $138M → $117M (-$20.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$875K |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$695K |
| 3 |
O
OrbiMed
New York
|
+$664K |
| 4 |
Renaissance Technologies
New York
|
+$384K |
| 5 |
PVI
Pura Vida Investments
New York
|
+$129K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$1.7M |
| 2 |
Morgan Stanley
New York
|
-$927K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$783K |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$594K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$336K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FDCDDQ
26
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $61.4K | -$1.32K | -180 | -2% |
|
|
CAC
27
Cowen and Company
New York
| $30K | +$37.8K | +5,166 | New |
|
|
SFS
28
Sowell Financial Services
North Little Rock,
Arkansas
| $8K | +$10.5K | +1,440 | New |
|
29
Osaic Holdings
Scottsdale,
Arizona
| $3K | +$4.4K | +601 | New |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | +$1.08K | +147 | +94% |
|
|
WAP
31
Wealthcare Advisory Partners
West Chester,
Pennsylvania
| $2K | +$2.58K | +352 | New |
|
|
CFGS
32
Concourse Financial Group Securities
Birmingham,
Alabama
| $1K | – | – | – |
|
|
TCM
33
Tekla Capital Management
Boston,
Massachusetts
| – | -$1.7M | -253,610 | Closed |
|
|
AFM
34
Anson Funds Management
Dallas,
Texas
| – | -$336K | -50,113 | Closed |
|
35
Squarepoint
New York
| – | -$158K | -23,633 | Closed |
|
36
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$74.2K | -10,144 | Closed |
|
|
TRCT
37
Tower Research Capital (TRC)
New York
| – | -$7K | -1,096 | Closed |
|
38
Bank of America
Charlotte,
North Carolina
| – | +$271 | +37 | New |
|
MIST Hedge Fund Activity: Q1 2021 in Review
34 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q1 2021, worth a combined $117M — down 15% from $138M a quarter earlier.
Fund positioning in MIST was balanced in Q1 2021: 5 funds opened new positions, 5 closed out, 10 added to existing stakes and 10 trimmed.
The largest buyer was Barclays, adding an estimated $875K. The largest seller was Tekla Capital Management, exiting entirely with an estimated $1.7M sold.
- 34 institutional investors held Milestone Pharmaceuticals (MIST) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $117M of Milestone Pharmaceuticals stock for Q1 2021, down 15% quarter-over-quarter.
- 5 funds opened new Milestone Pharmaceuticals positions in Q1 2021 and 5 closed out, a net change of 0 holders.
- The largest Milestone Pharmaceuticals buyer in Q1 2021 was Barclays, an estimated $875K added.
- The largest Milestone Pharmaceuticals seller in Q1 2021 was Tekla Capital Management, an estimated $1.7M sold.
Based on aggregated 13F filings for Q1 2021.